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ROLE OF CLINICAL METHODS, CHEST SKIAGRAM, SPUTUM 
MICROSCOPY AND PCR IN DIAGNOSIS OF PNEUMOCYSTIS 
JIROVECI PNEUMONIA IN HIV PATIENTS WITH CD4 COUNT 
LESS THAN 200 AND THE CLINICAL OUTCOME ‐A 
COMPARATIVE STUDY IN  TERTIARY CARE HOSPITAL 
Background : 
Pneumocystis jiroveci Pneumonia (PCP)  is one of the most predominant 
opportunistic infections occurring in HIV patients with CD4  count is less than 
200.Even though Chest radiograph findings may be normal in 10-39% of PCP 
patients, it is commonly used for diagnosis in resource limited settings. The 
other diagnosis methods are Gomori Methanamine Silver(GMS) staining, PCR. 
Among them, GMS is considered as the gold standard test in diagnosing PCP.   
AIM & OBJECTIVES: 
1) Comparing role of clinical diagnosis, chest radiography, sputum 
microscopy and polymerase chain reaction for Pneumocystis jiroveci 
Pneumonia in HIV seropositive patients with CD4 less than 200. 
2) To know the clinical outcome of  PCP patients after treatment in 
our centre 
 
STUDY DESIGN:  
Prospective cohort study  
 INCLUSION CRITERIA: 
1)  All HIV seropositive inpatients with CD4 count less than 200 cells/µL 
2) Age > 18 years 
 
EXCLUSION CRITERIA: 
1) HIV patients with CD 4 count > 200 cells/ µL  
2) Age < 18 years 
3) Patients with sputum positive pulmonary tuberculosis 
METHODS: 
1) Recruitment of patients as per inclusion criteria 
2) Thorough clinical examination & pulse oximetry 
3) Taking Chest x ray PA view 
4) sputum collection after hypertonic saline nebulisation 
5) Subjecting one sample of sputum for Gomori Methanamine Silver 
staining &another sample for Polymerase Chain Reaction 
7) Follow up the clinical course of patients after treatment  
8) Analysis of data using SPSS  
 
Results : 
Out of 151 HIV seropositive patients examined clinically ,81 individuals 
were diagnosed as PCP patients. But the sputum microscopy with Gomori 
methenamine silver staining which was taken as gold standard test diagnosed 41 
cases of PCP only.PCR was positive in 2 more patients who were missed in 
GMS staining 
sputum PCR is having the highest sensitivity (100%), highest specificity 
(97%),highest positive predictive value (93%) and also highest negative 
predictive value(100%). 
Among 90  PCP patients diagnosed clinically ,74 of 90(82.2%) patients 
recovered from the illness after treatment&16 0f 90(17.8%) patients died due to 
illness. 
Conclusion: 
PCR or GMS staining should be used for diagnosing PCP whenever 
possible and to detect all cases of PCP in HIV patients without missing. 
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INTRODUCTION 
 
Pneumocystis jiroveci Pneumonia is one of the most predominant 
opportunistic infections occurring in immunocompromised individuals 
especially HIV seropositive patients.1 Occurrence of Pneumocystis 
jiroveci Pneumonia is usually seen when the CD 4 lymphocyte count is 
less than 200 cells /microliter. 
 Before the era of prophylaxis, PCP was seen in 60 % of people as 
an AIDS defining illness and also it was noted in 80% of people living 
with HIV/AIDS. 
The incidence of PCP is in a decreasing trend because of the 
prophylaxis, early diagnosis of HIV/AIDS by well-organized 
Government programme and HAART (Highly Active Anti-Retroviral 
Therapy).  
 
 
An US study demonstrated that the PCP incidence had declined 
from 13 % in 1994 to 3 %3.2A Swiss study also noted the decline in PCP 
incidence (i.e. 30% reduction) during the period of 1995-97.3 
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In India, PCP affects 20 to 30% of AIDS patients and the mortality 
due to PCP is around 20 to 40 %. Figure 1.1 shows the occurrence of 
various opportunistic infections in India. 
                                               Figure 1.1 
 
PCP usually occurs when the CD 4 count becomes less than 200 
cells/cubic millimeter.fig 1.2 
 
Figure 1.2 
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The clinical features of PCP are non-specific. The onset is usually 
indolent. The most common symptoms are cough mostly without sputum 
production, breathlessness and fever.  
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Respiratory systemic examination may be normal at rest in mild 
cases. Tachypnea, tachycardia and basal crackles are the common signs 
elicited in clinical examination. 
Chest skiagram may be normal in 10 to 39% cases. The common 
radiological manifestations seen in chest skiagram or computed 
tomogram are  
1. Bilateral diffuse perihilar infiltrates 
2. Bilateral airspace consolidations 
3. Pneumotoceles 
4. Pneumomediastinum 
5. Pneumothorax 
6. Subcutaneous emphysema 
Clinical manifestations and radiological features are used as 
diagnostic methods in resource limited settings. However, the diagnostic 
method of choice is demonstration of organism in clinical specimen. If 
sputum is not available, induction of sputum production with hypertonic 
saline or bronchoalveolar lavage is done. 
Since Pneumocystis jiroveci is a non-cultivable fungus, sputum 
microscopy using various staining methods including Gomori’s 
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Methenamine Silver(GMS), Giemsa, toluidine blue and certain 
fluorescent brightners like calcoflour white and is used worldwide. 
Among them Gomori’s Methenamine Silver staining is considered as 
gold standard. 
PCR can be more efficient than immunofluorescence technique.4It 
was first evaluated by Wakefield et al. to increase the sensitivity and 
specificity to the PCP diagnosis.5 
In resource limited developing countries, because of lack of 
availability and cost factor, instead of microbiological and PCR testing, 
clinical manifestations and radiological features are used for diagnosing 
PCP. And also microscopic examination and PCR testing are labour 
intensive requiring trained personnel and infrastructure.  
Our NACO (National AIDS Control Organization) guidelines are 
also following the presumptive diagnosis of PCP and insist on earlier 
treatment.  
So there is a necessity to evaluate the role of clinical diagnosis, 
radiological diagnosis, sputum microscopy using Gomori’s Methenamine 
silver staining and PCR technique in diagnosis of PCP in HIV 
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seropositive individuals especially with CD4 T lymphocytes count < 200 
cells/cubic mm. 
This study has been done in Government Hospital of Thoracic 
Medicine (GHTM), Tambaram Sanatorium, Chennai.  The hospital has 33 
wards, of which 11 wards are especially for HIV patients, and 22 wards 
have patients with TB and other respiratory diseases in addition to the 
Outpatient Departments (OPDs). 
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GHTM is not only a premier institution attached to Stanley 
Medical College but also is uniquely placed as a Centre of Excellence 
(COE) in HIV/AIDS training because of the lot of complex clinical cases 
presenting every day at GHTM. This institution is   having NABL 
accredited microbiology laboratory.  
This is a reputed tertiary care center for HIV / AIDS patients in 
Tamilnadu.  GHTM is well equipped to deal with every type of HIV-
related illness and to provide high-level care and support for all chest 
diseases. 
So there is necessity to evaluate the role of clinical diagnosis, 
radiological diagnosis, sputum microscopy using Gomori’s Methenamine 
silver staining and PCR technique in diagnosis of PCP in HIV 
seropositive individuals especially with CD4 T lymphocytes count < 200 
cells/cubic mm. 
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REVIEW OF LITERATURE 
 
Pneumocystis jiroveci: 
Pnuemocystis organism was first identified and reported by Chagas 
in 1909(6). It was mistaken for Trypanasoma cruzi’s morphological form, 
but in further studies it was well established that the organism was not a 
trypanazoma and it was a new species, named Pneumocystis carinii 7. 
Because of molecular biological techniques, Phylogenetic 
determinations based on gene sequences allowed the fungal identity of 
the genus and gave the species distinction. Among them, Pneumocystis 
carinii infects rat but Pneumocystis jiroveci is the species infecting 
humans. 6  
In 1976  Frenkel was the first researcher who proposed the name 
Pneumocystis jiroveci. 
Many clinicians and researchers raised issues about the 
nomenclature change from Pneumocystis carinii to Pneumocystis 
jiroveci. Inspite of these controversies, scientific and biological evidences 
made general acceptance of the current nomenclature. 7 
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Three Structural forms of Pneumocystis jiroveci are 
1. Cyst form 
       2. Sporozoite 
       3. Trophozoite 
Cyst form is spherical or ovoid in shape and diameter is 4-6 micro 
meter and contains up to 8 sporozoites. The structure of the cystic form of 
PCP is shown in fig 2.1 
Figure 2.1 
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Trophozoite is thin walled represent as excysted sporozoite. This 
pathogen is specific to humans; it will not infect other animals. Other 
species parasitize in animals have not shown to infect human.8 
Structure of Pneumocystis jiroveci:  
Cell wall consists of 3 layers, outer layer made up of glycoprotein. 
It helps in the attachment of pneumocystis to host cell [type 1 
pneumocyte]. Surface glycoprotein has different molecular weight these 
are 110 to 120, 45 to 50, 35 to 45, 20 to 27 KD. 
Most prominent feature of human derived pneumocystis is staining 
intensely in band between 35 to45 KD and it is the most common band 
found in lung and bronchoalveolar fluid of patient infected with 
pneumocystis. 
The structure of Pneumocystis jiroveci trophozoite is shown in 
figure 2.2. 
                                         
 
 
  
13
Figure 2.2 
 
The cell wall contains cholesterol not ergosterol. Although 
classified as fungus, P.jirovecii does not contain ergosterol, instead it 
synthesizes two distinct sterols called 24 alkyl sterol [(24-methylcholest-
7-en-3β-ol and 24-ethylcholest-7-en-3β-ol] which it can scavenge from 
lung macrophages.9Thus pathogen specific sterol is important for survival 
and proliferation. 
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The inefficacy of azoles against p.jirovecii is explained because of 
24 alkyl sterol synthesis by the organisms. Mammals cannot synthesize 
24 alkyl sterol so their biosynthesis in p.jirovecii is attractive target for 
the development of drugs against it. 
 Cell wall is carbohydrate rich with glucose, mannose and β-1, 3-
glucon. β-1, 3-glucon synthase which mediate  polymerization, so 
inhibitors of  β-1, 3-glucon synthase are effective in clearing cyst of 
pneumocystis from lung of infected patient. 
Signal transduction found in pneumocystis are cdc2 cyclin derived 
kinase, cdc13 B-type kinase, cdc25 mitotic phosphatase and 
pneumocystis mitogen activated protein kinase. 
After adhering to alveolar epithelium it activates signalling 
pathway which is responsible for mating and proliferation of organism. 
Currently some of the molecules are under intense study which includes 
dihydrofolate reductase, thymdylate synthase, inosine monophosphate 
dehydrogenase and lanosetrol 14α-demethylase. 
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LIFE CYCLE: 
 There are various articles on the life cycle of P.jirovecii with 
different views and developmental stages. Wanderley de Souza et al have 
demonstrated a life cycle by incorporating the details and data were 
obtained using electron microscopy. This has been widely accepted 
(Figure 2.3). 
There is no clear data about the infective form of P.jirovecii. But 
the well accepted route of transmission is airborne. 
Life cycle is characterised by two different developmental stages 17 
1. Mature cyst     
2. Trophozoite  
  
16
The origin of Trophozoite form is directly from the mature cyst 
which contains eight spherical intracystic bodies, which in turn developed 
into 8 trophozoites.  
Two other intermediate cystic forms have been demonstrated 
including developing or empty cysts. Some of the trophozoites mature 
and develops into cyst. Thus the cycle is repeated. 
Sexual and asexual intermediate forms have been also described in-
between. 
Figure 2.3 
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Most of the scientific papers postulating the life cycle are based on 
animal studies or by passing the organism in tissue culture. But the 
organism especially P.jirovecii the human derived species has not shown 
growth consistently in vitro 
MOLECULAR BIOLOGY: 
Both unique and some common antigens are expressed by 
P.jirovecii in different hosts. By genetic differentiation so many surface 
glycoprotein (MSG) types has been demonstrated in humans. And also 
GP 45-55 may have significant role in human infection 
Each genomic copy of an MSG has an upstream highly conserved 
expression site. And also it includes a specific downstream segment 
encoding the differentiating antigenic property of each clone. 
EPIDEMOLOGY: 
PCP occurs in four groups of immune compromised host: 
1. Congenital, caused by defective antibody synthesis 
2. Induced, by drugs causing immunosuppression including 
corticosteroids 
3. Acquired, affecting HIV population as an opportunistic infection 
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4. Nutritionally deficient, usually seen in neonates as epidemic 
CONDITIONS WITH RISK OF PCP: 
1. HIV/AIDS 
2. Organ transplantation 
3. Hematologic manifestations 
4. Prolonged steroid therapy 
5. Radiotherapy  
6. Congenital immunodeficiencies 
7. Protein energy malnutrition 
8. Prematurity 
 
A retrospective study in 116 HIV seronegative individuals with 
PCP shows 30.2% associated with hematologic malignancies, 25% with 
organ transplant, 12.9% with solid malignant tumours and 9.5% with 
other disorders. 
A retrospective study in China showed the increase in incidence of 
PCP. 
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Epidemiologic research in paediatric population suggests that PCP 
can occur in children as a result of simultaneous viral infection.  
Beard et al described different strains in infants on comparing to 
HIV patients with PCP. 
With the help of genetic probes several molecular studies 
conducted in animals and humans have suggested that both reinfection 
and reactivation of latent P.jirovecii infection play a role in incidence of 
disease in treated PCP patients. 
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Virulence and pathogenesis of p.jirovecii 
Attachment of trophozoite form of p.jirovecii to lung epithelial 
cells (type 1 pneumocyte) plays critical role in development of disease in 
human .Attachment is mediated through variety of molecules including 
fibronectin, vitronectin, laminin, and mannose receptor.  
Binding is facilitated by p.jirovecii extracellular matrix. Majority 
of alveolar surface is covered by type 1 pneumocytes and it is responsible 
for gas exchange.18 
In the susceptible host attachment of p.jirovecii causes secretion of 
proteolytic enzymes such as chymase or reactive oxygen species which 
leads to proliferation of the organism and impaired lung cell replication  
P.jirovecii induces alteration in bio physiology of lung surfactant 
and may have effect on alveolar macrophages and lung monocyte.  
Organism by coating itself by host derived glycoprotein such as 
surfactant protein – A and soluble form of the macrophage mannose 
receptor leads to delay in recognition and destruction by host immune 
system. 
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P.jirovecii replicates extracellularly causes host cell damage, 
resulting in cell lysis and rupture which leads to impairment in oxygen 
diffusion. Lung basement membrane damage generates a characteristic 
foamy exudates and interstitial leukemic infiltration. 
  Granulomatous inflammation is seen in up to 5% of lung biopsy 
from human immunodeficiency virus (HIV)-infected patients  
P.jirovecii fails to cause disease in normal host because it is an 
opportunistic pathogen .It causes disease only when host immune system 
is compromised. 
Dr Icenhour has shown that p.jirovecii has melanin in their cell 
wall it causes alteration in host immune response and melanised 
pneumocystis retains viability better than native pneumocystis when 
incubated with phagocytes 
CLINICAL FEATURES: 
The symptoms and signs of PCP may be subtle. High index of 
suspicion is required for diagnosis especially in HIV negative individuals. 
Only 50% of patients report the classic triad of dry cough, exertional 
dyspnoea and fever.  
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In a clinical review of 93 PCP patients, only 53% had the classical 
triad of cough, breathlessness and fever. 
Usually the progression of symptoms is slow. It takes over weeks 
to months to progress. But in HIV seropositive patients there is rapid 
onset and progression of symptoms.  
The patients who had the prior history of PCP episode can mostly 
identify a recurrent episode but the patients who are having a new episode 
of PCP usually refer it as non-resolving severe cold. 
Systemic examination of respiratory part may be normal or fine dry 
crackles can be heard on auscultation. Spontaneous pneumothorax may 
be seen in 2-6% of cases. 
Serum LDH elevation can occur but its non-specific. It can also be 
used as evidence of severity. It also has a prognostic role as demonstrated 
by Forrest et al.11 
Chouaid et al found hypoxia in almost all patients with PCP in a 
study.12 
 SpO2 measurement may show a decrease <90% in rest or during 
exercise. Arterial blood gas analysis usually shows reduced PaO2 
(hypoxemia) or an increased alveolar to arterial difference ([A-a] DO2). 
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GRADING PCP BY ABG: 
SEVERITY GRADING [A-a]DO2 PaO2(mmHg) 
MILD <35 >70 
MODERATE 35-45 >70 
SEVERE >45 >50 
 
RADIOLOGICAL FEATURES: 
 The chest skiagram plays a vital role in the diagnosis of PCP. 
There is no pathognomonic radiological feature or pattern for PCP 
diagnosis.19  Chest X-ray may be normal in 10-39% individuals. 
The common radiological pattern seen in chest skiagram is 
bilateral, perihilar, diffuse infiltrate. It may progress to consolidation 
pattern involving upper and lower zones (Figure 2.4). Air bronchogram 
may be appreciated. Pneumatoceles and cyst may be seen. 
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Figure 2.4 
 
 
 
Depending upon severity and duration of illness, pneumothorax, 
pneumomediastinum, and subcutaneous emphysema can occur  
(Figure 2.5). 
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Figure 2.5 
 
 
Unusual patterns like nodules, unilateral infiltrates or lobar 
consolidation may mimic atypical pneumonia 
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Upper lobe predominance is noted with the presence of cystic 
changes in patients those who underwent prophylaxis or therapy with 
inhaled pentamidine. 
In HRCT images the ground glass attenuation is the hallmark of 
PCP. More than 90% of patients show GGO which denotes an exudative 
alveolitis. GGO refers to parenchymal opacification not obscuring 
underlying pulmonary architecture (Figure 2.6). 
 
Figure 2.6 
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Mosaic attenuation is seen in around 56% patients. Interlobar septal 
thickening, small cysts, mediastinal emphysema, pneumothorax, 
subcutaneous emphysema can be seen in HRCT chest images. 
A review of HRCT chest in 39 patients by Kuhlman et al showed 
GGO (26%), ILD (18%) and bilateral patchy parenchymal opacity (56%) 
in PCP patients. 
Along with clinical features the presence of GGO on HRCT chest 
images in HIV patients with CD4 count less than 200 cells/cumm is 
virtually diagnostic of PCP with around 94% accuracy. 
Staining methods: 
Gomori Methenamine blue [GMS], Giemsa, toludine O blue, 
papanicolaou, fungi fluor & immunofluorescent antigen[IFA].  
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However GMS &IFA are gold standards for detection of 
p.jirovecii. In fungi fluor stain cyst shows parenthesis or comma like 
internal dots surrounded by cyst walls, one must know these two 
structures before diagnosing them as p.jirovecii.  
In Gram stain Cyst appears as vacuolated unstained round structure 
&trophozoites as pinkish darts 
In Giemsa stain Trophozoites as dotted particles that are small and 
pleomorphic showing pale blue cytoplasm and nucleus as purplish in 
colour. Cysts appear as rounded and vacuolated. 
In Gomori Methenamine stain Cyst appears dark staining (greyish 
brown or black), collapsed with cup shaped appearance. Sometimes black 
dots appear in cysts (Figure 2.7). 
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Figure 2.7 
 
Papanicolaou stain:  
It is non-fluorescence stain so cyst structure appear clusters of 
haloes.  
Immunofluorescence stain:  
Round to oval shaped cyst embedded in extracellular matrix 
trophozoite and sporozoite appear as fluorescent apple green colour 
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Stain  sensitivity specificity 
calcofluor 73.8% 99.6% 
Gomori methenamine silver  79.4% 99.2% 
Diff –quik  49.2% 99.6% 
Merifluor  90.8% 81.9% 
 
Only Calcofluor and Gomori’s Methenamine stain had positive and 
negative predictive values of  ≥ 90%. 
Calcofluor white is a fluorescent stain, in which the active 
ingredient is cellufluor. The cellufluor non-specifically binds to beta-
linked polysaccharides like chitin and cellulose. This method is used for 
the direct visualization of fungi in clinical samples. 
Immunofluorescent staining methods utilizing antibodies directed 
against Pneumocystis jiroveci is also being used in many centres to 
directly visualise the organism in clinical samples. 
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Procop et al., demonstrated in their study that the Calcofluor white 
stains and GMS stains had the best parameters to use routinely in PCP 
diagnosis. Even though these staining methods were less sensitive than 
the immunofluorescent assay, they had high specificity and more 
acceptable predictive values.13 
 
LUNG BIOPSY: 
VATS affords the same yield as open lung biopsy done via 
thoracotomy.  
Especially in HIV seronegative patients, the invasive techniques 
are often needed to diagnose PCP. 
The demonstration of organism is essential in transplant recipients. 
In the adult patients, the disease predominantly occurs as an alveolar 
process. The airspaces are usually filled with foamy eosinophilic 
exudative material and appear to be honeycombed.  
The alveolar exudate consists of organisms itself, lot of surface 
glycoprotein, proteinaceous exudate and debris of macrophages and other 
inflammatory cells. Simultaneously, the alveolar interstitium is infiltrated 
by polymorphonuclear leukocytes and lymphocytes. 
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PULSE OXIMETRY: 
Pulse oximetry used in exercise test may be useful in excluding 
PCP in doubtful cases. 
In a study, exercise testing in 85 HIV seronegative patients with 
suspected PCP found that 3% desaturation with exercise was 100% 
sensitive and 70% specific12.  
This can be used as a good screening tool in outpatient department. 
Arterial blood gas analysis can be done and utilized as a tool for 
severity grading. 
PCR: 
 In the 1990s, PCR was introduced and it facilitated the diagnosis of 
P. jiroveci by showing increased sensitivity, specificity and predictive 
values, and compared to staining techniques and monoclonal antibodies 
and by reducing the necessity for trained personnel to differentiate  
P. jiroveci from common artefacts and other non-specific staining. 
Even though the results of PCR on routine sputum examination, 
induced sputum with hypertonic saline are differing from BAL 
specimens, it is likely to be more efficient in diagnosis of PCP when 
comparing to the immunofluorescent test. 
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The use of PCR for diagnosis of PCP has been increasingly 
reported on in the past ten years.  
PCR is valuable tool for describing natural history of disease and 
the PCP epidemiology (Figure 2.8). 
 
Figure 2.8 
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The prophylactic therapy given for PCP may decrease the yield of 
microscopic diagnostic method 
Various clinical studies showed that PCR is more sensitive than 
conventional diagnostic methods14, 15. 
 Meja Rabodonirina et al have documented the sensitivity and 
specificity for the nested PCR method as 100% and 77% respectively. 
The same study showed the positive  predictive value and negative 
predictive value were 54% and 100% respectively16. 
DNA extraction and amplication are the two essential steps of 
PCR.  
After DNA extraction by denaturation in a thermocycler, DNA 
amplication using primers, T99 polymerase were done usually in two 
steps. DNA extraction and amplication are usually done in three separate 
rooms to avoid contamination with the specimen.  
At last, PCR end products are subjected to agarose gel 
electrophoresis. Then they are stained with ethidine bromide and finally 
visualised under ultra violet light. 
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Barbara Alexander et al has reported the sensitivity (93%), 
specificity (91%), positive predictive value (59%) and negative predictive 
value (99%) for PCR diagnosis of PCP using pneumocystis MLSU 
(mitochondrial ribosomal large sub-unit) as the target specimen. 
In recent years, large number of research papers is demonstrating 
P.jirovecii genes amplication by PCR.20 
 The gene encoding mitochondrial rRNA, chromosomal rRNA and 
thymidylate has been implicated in various PCR studies. They have 
improved the sensitivity of detecting Pneumocystis jiroveci.21 
Cartwright et al have showed in a study, in 133 BAL specimens the 
sensitivity of PCR was 100% (21 of 21 samples) and specificity of 99% 
(132 of 133 samples). In that same study, the specificity of PCR in 
induced sputum was 98%. 
In some studies comparing microscopy and PCR for PCP 
diagnosis, no real advantage of nested PCR, with regard to sensitivity and 
specificity compared to those of microscopic diagnosis, could be reported 
when bronchoalveolar samples were examined.45, 46, and 47 
But for HIV patients the majority of studies reveal higher 
sensitivity for both single and nested PCR than for microscopic staining 
when induced sputum is obtained. 
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The first step in the diagnosis of PCP is the realization that the 
patient is at risk for the opportunistic infection. 
The very first procedure should be a routine sputum smear 
examination for Gram staining, Acid fast staining and fungal staining and 
cultures. 
Then, the choice of diagnostic test depends on the patient status 
that is the ability to cooperate with sputum induction, the distribution of 
respiratory disease, and the urgency of diagnosis. 
Induced sputum should be obtained whenever possible to diagnose 
PCP. 23 
If the patient is on respiratory failure or the sputum examination is 
negative, BAL should be done as earlier as possible24 
EXTRAPULMONARY PNEUMOCYSTOSIS:  
Two reviews from New York revealed that incidence of extra 
pulmonary pneumocystis jiroveci infection is 0.5 % from 3%, but it is 
usually underdiagnosed if patient dies without post mortem. 
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The common sites involved are reticuloendothelial system (lymph 
nodes, spleen, liver and bone marrow) Gastro intestinal tract and genito-
urinary tract.25 
It may develop concomitantly with PCP or independently. 
Differential diagnosis of P.jiroveci pneumonia 
Tuberculosis 
Viral Pneumonia 
Mycobacterium interacellulare (MAC) Infection 
Acute Respiratory Distress Syndrome 
Mycoplasma Infections 
Cytomegalovirus 
Lymphocytic Interstitial Pneumonia 
Pulmonary Embolism 
Legionellosis 
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TREATMENT: 
Therapy of HIV infection has undergone remarkable changes in the 
past 10 years with advances in HAART and prophylactic therapy and 
associated significant improvements in survival. With these advances, the 
incidence of PCP has remarkably fell down, but it is still the most 
common opportunistic infections among HIV seropositive patients. 
Treatment should be initiated as soon as the presumptive diagnosis 
of PCP is aimed because the infection is rapidly progressive and the 
mortality rate is quite high. 
The drug of choice of PCP is trimethoprim-sulfamethoxazole. It is 
the agent of choice for extra pulmonary infection in all individuals.26 
TMP-SMX has the tremendous penetration in tissues and 
expeditious clinical response. 
The usual dose is 15 to 20 mg/kg/day of trimethoprim. Oral 
administration is having comparable bioavailability with that of 
intravenous therapy.  
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TMP-SMX sequentially blocks two enzymes in folate metabolism 
essential for DNA synthesis: 1.Dihydrofolate reductase (DHFR) 
2.Dihydropteroate synthetase (DHPS)27. 
If there is severe hypoxia or gastro-intestinal disturbances, 
intravenous TMP-SMX therapy administration should begin. 
 Serum SMX level above 200microgram/ml is associated with 
adverse effects particularly bone marrow suppression.   
It is not necessary to discontinue therapy because of mild side 
effects including rash, neutropenia, and liver enzymes elevation if the 
patients is tolerating well. 
Nephrotoxicity is the major adverse event occurring frequently in 
the renal transplant recipients. This can be both dose related event and 
also idiosyncratic. The dose of TMP-SMX reduction should be done. 3-5 
mg/kg/day are sufficient for patients with GFR around 10‐50 ml/min. 
Pentamidine isethionate is the alternate drug for PCP treatment. 
The usual dose is 4mg/kg/day as slow intravenous infusion in 5% 
dextrose.  
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Pentamidine attains the therapeutic concentrations in the lung 
parenchyma slowly (in a week) because the extrpulmonary tissue binding 
is high.it also has long half-life (6.4 hrs.). Because of above said reasons 
the accumulation and toxicity is common with the drug. 
The adverse events including pancreatitis, diabetes, transient 
hypoglycaemia, hypotension, renal insufficiency are due to idiosyncrasy. 
It is better to avoid this drug  in pancreatic transplant patients. 
A meta-analysis study suggested that therapy with clindamycin-
primaquine combination is associated with a more favourable outcome 
when compared with pentamidine therapy. 
Breakthrough infection has been seen in a few patients receiving 
aerosolized and intravenous pentamidine therapy as prophylaxis 
(especially in the upper lobes). These breakthrough infections are in 
patients receiving primary prophylaxis after lung transplantation or in 
HIV seropositive patients who have not yet received antibiotic, in 
Cytomegalovirus -infected persons, or in secondary prophylaxis after 
inadequate clearance of infections. 
  
41
 
When TMP-SMX, dapsone-TMP and clindamycin-primaquine 
were compared in mild to moderate PCP patients, there were no 
significant differences in terms of either treatment failure or therapy-
limiting toxicity; 54 % of the patients did not finish a complete course of 
treatment, predominantly because of drug toxicity.27 
Fred R Sattler et al have compared co-trimaxazole therapy with 
pentamidine therapy for treating PCP in HIV seropositive individuals and 
concluded that survival rate was more and quick improvement in 
oxygenation was seen with co-trimaxazole therapy.28 
HIV seropositive patients who are clinically diagnosed as PCP are 
similar to those who had microscopic diagnosis and that empirical 
therapy for PCP in this group results in similar outcomes.29 
Dapsone along with trimethoprim is another option for treatment of 
PCP. 
ATOVAQUONE (750 mg PO TDS) has also been approved by 
FDA treatment of PCP 
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Trimetrexate, clindamycin- primaquine combination have also 
been approved for treatment of PCP. 
Helweg-Larsen J et al. in a tri-centre cohort study have compared 
pentamidine therapy with clindamycin/primaquine combination therapy 
for PCP treatment and showed that clindamycin/primaquine was superior 
to pentamidine therapy and that combination could be used for patients 
not tolerating or failing with co-trimoxozole therapy.29 
 Interferon, colony stimulating factors like (G-CSF), (GM-CSF) 
have been studied in animals and showed some response in terms of 
reduction in the amount of pneumocystis.30, 31 
The recommended duration of treatment is 3weeks in HIV 
seropositive patients and 2 weeks in HIV seronegative individuals. 
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Bennett et al., compared PCP patients treated empirically with PCP 
patients treated after microscopic confirmation in 56 hospitals and 
revealed that empirical treatment had a significant greater death rate.32 
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The therapeutic response is usually excellent in patients receiving a 
diagnosis before respiratory insufficiency. The ability to reduce immune 
suppression also improves the rapidity of  infection clearance. 
Deciding whether a patient is responding to therapy may be 
difficult. It is vital to remember that oxygenation typically reaches a nadir 
approximately 72 hours after treatment is initiated. Because it generally 
takes several days for clinical improvement, therapy usually should not 
be changed for at least four to five days. 
  If clinical improvement is not seen by days 4 to 5 of TMP-SMX 
therapy or 5 to 7 of pentamidine therapy should suggest the presence of 
some another process: Fibrosis, ARDS, abscess, bronchial obstruction, 
drug hypersensitivity and bronchogenic carcinoma.  
Bronchoalveolar lavage and biopsy for microbiologic staining and 
pathology, or computed tomography of chest may be revealing in these 
individuals. 
Prognosis of P.jirovecii pneumonia: 
Worst prognosis is noted in patient without HIV infection and 
mortality rate is 30%-50%. In patients with HIV infection mortality 
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depends on severity of disease at presentation and mortality rate is  
10%-20%. 
In various studies, worst prognosis is showed in patients presented 
with concurrent pulmonary disease, in patients with pneumothorax and 
who require mechanical ventilation 
The higher mortality is mainly because of delay in diagnosis and 
delay in initiation of appropriate treatment regimen. 
Complications 
The common complications of PCP are  
¾ Respiratory failure 
(May occur despite with appropriate treatment) 
¾ Acute respiratory distress syndrome 
¾ Pneumothorax  
(May be due to spontaneous or secondary to barotraumas during 
positive –pressure ventilation) 
¾ Pneumomediastinum 
¾ Worsening of condition after starting therapy 
¾ Pulmonary cyst formation 
¾ Haematogenous spread 
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¾ Extra pulmonary infection  
¾ Dissemination can occur in both HIV non HIV infected patients 
¾ Most common sites of involvement are lymph nodes, bone marrow, 
liver, spleen, gut and eye lesion (choroiditis) 
 
PROPHYLAXIS: 
 NACO guidelines in India and CDC guidelines of USA 
recommend primary prophylaxis for PCP in HIV seropositive patients 
with CD4 count <200/micro litre, Secondary prophylaxis is 
recommended after treatment of PCP. For both primary and secondary 
prophylaxis, the drug of choice is TMP-SMX. 
The other agents used for prophylaxis are dapsone, dapsone + 
pyrimethamine combination, pentamidine, atovaquone etc. 
  
47
 
Drug(s), Dose, Route 
First Choice  
TMP-SMX, 1 DS tablet or 1 SS tablet qd PO 
Other Agents  
Dapsone, 50 mg bid or 100 mg qd PO
Dapsone, 50 mg qd PO; plus pyrimethamine, 50 mg weekly 
PO; plus leucovorin, 25 mg weekly PO 
Dapsone, 200 mg weekly PO; plus pyrimethamine, 75 mg 
weekly PO; plus leucovorin, 25 mg weekly PO 
Pentamidine, 300 mg monthly via nebulizer 
Atovaquone, 1500 mg qd PO 
TMP-SMX, 1 DS tablet three times weekly PO 
 
 
A large cohort study done by Phair et al in asymptomatic HIV 
seropositive homosexuals not under prophylaxis for PCP showed 8.4% of 
patients with CD 4 count less than 200 cells/microliter developed PCP 
within 6 months and 18.4%developed PCP within 12 months. 
CORTICOSETROIDS IN PCP TREATMENT: 
 Corticosteroids administration in the first 72 hours of PCP 
management can prevent respiratory failure and death in AIDS patients. 
Patients with hypoxia (PaO2<70 mmhg) and [A-a] DO2 > 35 mmhg 
should get corticosteroid adjuvant therapy.33,34 
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Some studies demonstrated corticosteroids usage in mechanically 
ventilated patients with PCP has shown reduction in the mortality from 
84 % to 39%. 
PREDNISOLONE  DAYS   DOSE 
    1-5    40mg BD 
    6-10    40mg OD 
    11-21    20mg OD 
Oral prednisolone if tolerable or intra venous methyl prednisolone 
can be given.  
Steroid therapy should be initiated within 72 hours of initiating 
antimicrobial treatment in an HIVseropositive patient with PCP if the 
partial pressure of arterial oxygen (PaO2) is less 70 mmHg or the 
alveolar-arterial oxygen difference (AaDO2) is more than 35. 
60 to 79 % mortality was reported for severe PCP in HIV 
seropositive patients who required ICU care in the pre – HAART (Highly 
Active Anti-Retroviral Treatment) era. But it has been reduced after 
HAART. 
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Sabha Radhi et al. have demonstrated overall mortality of 11.6% 
for hospitalised PCP patients and 29% mortality especially for patients 
admitted in ICU.35 
Helweg-Larsen J et al.  have demonstrated in a study done in three 
different centres including Copenhagen, Milan and London that the rate 
of concomitant LRI with co-trimaxazole was 10%, 
clindamycin/primaquine combination was 5% and with pentamidine was 
quite high (15%). 36  
A study in San Francisco showed 55 % mortality for patients with 
PCP admitted in ICU compared to 63% shown in the same hospital 
previously in pre HAART era. 
In the recent HAART era, predictors of clinical outcome especially 
death have not changed. Development of pneumothorax and 
pneumomediastinum, hypoalbuminemia, need for mechanical ventilation 
are the predictors of poor outcome in many studies.  
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Mallal SA et al demonstrated in pre HAART era ,PCP found in 
newly diagnosed HIV patients had more severe form of PCP with low 
PaO2 and higher requirement of mechanical ventilation  comparing to 
PCP in known HIV patients.37 
The clinical features and outcomes of PCP differ in HIV 
seropositive and HIV seronegative patients. But, there are only limited 
data on the efficacy of adjunctive corticosteroid therapy in HIV 
seronegative patients with PCP.   
No randomized trials have been conducted. In contrast to the data 
for HIV seropositive patients, the data for HIV seronegative PCP patients 
showed that adjuvant corticosteroid therapy might not improve outcomes. 
J Randall Curtis et al., conducted a study about the outcome of 
PCP with respiratory failure requiring assisted ventilation .They found the 
hospital survival rate was approximately 40 % which was twofold 
improvement from the years 1992 to 1995.38 
There is no dedicated prognostic system with significant accuracy 
to determine which patients will be benefitted by mechanical ventilation. 
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AIM & OBJECTIVES 
 
1) Comparing role of clinical diagnosis, chest radiography, and 
sputum microscopy and polymerase chain reaction for 
Pneumocystis jiroveci Pneumonia in induced sputum in HIV 
seropositive patients with CD4 less than 200. 
 
2) To know the clinical outcome of PCP patients after treatment in 
our centre. 
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MATERIALS AND METHODS 
 
STUDY DESIGN:  
Prospective cohort study  
INCLUSION CRITERIA: 
1)  All HIV seropositive inpatients with CD4 count less than 200 
cells/µL 
2) Age > 18 years 
EXCLUSION CRITERIA: 
1) HIV patients with CD 4 count > 200 cells/ µL  
2) Age < 18 years 
3) Patients with sputum positive pulmonary tuberculosis 
4) Unconsented patients 
5) Comatose patients  
SITE OF INVESTIGATION: 
Govt. Hospital of Thoracic Medicine, Tambaram Sanatorium, 
Chennai 
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STUDY PERIOD: 
January 2012 to May 2012 
METHODS: 
1) 151 HIV seropositive patients were recruited for study as per 
inclusion criteria 
2) Thorough clinical examination including general and systemic 
examination was done meticulously with vital signs monitoring & SpO2 
was measured with pulse oximetry  
Clinical diagnosis:  
Clinical diagnosis of PCP was done based on presence of following 
signs and symptoms suggestive of PCP. 
Symptoms  
 A. Cough with or without sputum production for more than two 
weeks  
B. Breathlessness  
C.  With or without fever  
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Signs 
A. Tachypnea  
B. With or without bibasilar crackles  
C. SPO2 < 90 % in ambient air or after exertion of 200 meter 
 walking 
3)  Chest x ray PA view was taken for each and every patient. 
Radiological diagnosis:  
Radiological diagnosis of PCP was made based on the presence of 
any one of the following radiological features suggestive of PCP in chest 
skiagram. 
 Bilateral perihilar infiltrates  
 Bilateral airspace consolidations  
 Pneumatoceles  
 Pneumomediastinum  
 Pneumothorax  
 Subcutaneous emphysema 
 
 
  
55
4) 3 to 5 ml of sputum collection in sterile container was done 
after hypertonic (3%) saline nebulisation using jet nebulizer 
for five minutes. This procedure was done in a separate 
room. 
5) One sample of sputum was subjected for Gomori 
Methenamine Silver staining and microscopic examination 
6) GMS staining method: 
 The slides were kept in a microwave oven for 40 seconds in 
a solution of 10% chromic acid, washed with distilled water 
and then rinsed with 1% sodium metabisulphite for 30 
seconds. 
Again the slides were washed with water and then placed in 
a Coplin jar containing 50 ml of Methenamine solution.  
Once again the slides were kept in microwave oven for 65 
seconds. After rinsing in water, the slides were treated with 
1% silver chloride for 5 seconds. 
 Again the slides were rinsed with distilled water, treated 
with 5% sodium thiosulfate for 1 minute and then 
counterstained with a light green working solution. 
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 Then they were cleared in xylene, covered with cover slips 
and subjected to light microscopy. 
7) Another sputum sample was subjected for Polymerase Chain 
Reaction (PCR) test targeting mitochondrial rRNA 
8) Polymerase Chain Reaction (PCR) test: 
 Induced Sputum specimens were first exposed with a 
mucolytic agent 0.0065 M dithiothreitol (DTT) and then 
centrifuged. The pellets were resuspended in one fifth of 
supernatant. 
 200 ml of pellets were lysed in equal volume of a lysis 
buffer containing 500mg of proteinase K.  
 Then DNA extraction was done using a specific kit. 
 Polymerase chain reaction was done by denaturation for 5 
minutes at 94 degree C followed by 35 cycles for one 
minute, 65 degree C for 1 minute and 72 degree C for one 
more minute in a thermocycler. 
 Oligonucleotide primers Paz102 and Paz102 H were used. 
They amplify a 346 base pair region of the gene. 
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 The nested round was performed using AZ 102X as forward 
primer and PAZ 102Y as reverse primer .This round 
amplifies a 267 base pair product.  
 Separate rooms were used to perform DNA extraction, PCR 
mixture preparation and DNA addition especially to avoid 
contamination. 
 For handling reagent transfers aerosol barrier tips were 
utilized. 
 All PCR products were put in 1.5 % agarose gel and 
visualised under ultra violet light. 
9) Sputum microscopy and PCR results were obtained in two 
days. 
10) All diagnosed patients were treated with oral TMP-SMX 15 
mg/mg/day in three divided doses and patients on respiratory     
failure were treated with corticosteroids additionally in 
intensive respiratory care unit along with non-invasive 
ventilation. 
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11) All patients under inpatient treatment were followed up 
clinically upto the completion of treatment for PCP and 
outcome were analysed 
        12) Analysis of data was done using SPSS 
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ETHICAL JUSTIFICATION 
 
The various investigations and procedures that will be used in this 
study will be as per protocol. The identity of each patient will be kept 
confidential. This study will not violate medical ethics in anyway and it 
will help to know the role of diagnostic methods in pneumocystis jiroveci 
pneumonia patients.      
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OBSERVATION AND RESULTS 
 
In the study on  ROLE OF CLINICAL METHODS, CHEST 
SKIAGRAM, SPUTUM MICROSCOPY AND PCR IN DIAGNOSIS OF 
PNEUMOCYSTIS JIROVECI PNEUMONIA IN HIV PATIENTS 
WITH CD4 COUNT LESS THAN 200 AND THE CLINICAL 
OUTCOME  between January 2012 to May 2012 
The following observations were made. 
Out of 151 HIV seropositive patients with low CD4 count  
(<200cells/cubic mm) examined clinically with symptom analysis, 
respiratory system examination and pulse oximetry, 81 individuals were 
diagnosed as PCP patients. But the sputum microscopy with Gomori 
methenamine silver staining which was taken as gold standard test 
diagnosed 41 cases of PCP only. 
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2 x 2 tabulation was used for calculation and following results were 
made for clinical diagnosis. 
 
Sensitivity     0.78     95% Confidence Interval (0.63 to 0.88) 
Specificity     0.55     95% Confidence Interval (0.46 to 0.64) 
Positive PV   0.40   95% Confidence Interval (0.30 to 0.50) 
Negative PV  0.87   95% Confidence Interval (0.77 to 0.93) 
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Chi square test was done.  
Confidence interval for sensitivity, specificity, positive predictive 
value and negative predictive value were calculated. 
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Chi square test showed the results of clinical diagnosis were 
significant. 
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RADIOLOGICAL DIAGNOSIS  
When Chest skiagram is as a diagnostic tool, radiological diagnosis 
of PCP was made in 40 patients out of 151 who had undergone chest 
skiagram. 
The calculated values for radiological diagnosis on comparing with 
GMS staining were: 
Sensitivity 0.60      95% Confidence Interval (0.59 to 0.82) 
Specificity 0.86       95% Confidence Interval (0.79 to 0.92) 
Positive PV 0.62   95% Confidence Interval (0.60 to 0.83) 
Negative PV 0.86    95% Confidence Interval (0.78 to 0.93) 
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Confidence interval for sensitivity, specificity, positive predictive 
value and negative predictive value were calculated. 
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Chi square test showed the results of Radiological diagnosis of 
PCP were significant. 
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Polymerase chain reaction (PCR): 
 
      Out of 151 patients who had undergone induced sputum for PCR, 
Diagnosis of PCP was made in 44 patients. The following results are 
derived from 2 x 2 tabulation. 
 Sensitivity       1.0      95% Confidence Interval (0.91 to 1.0) 
 Specificity      0.97    95% Confidence Interval (0.92 to 0.99) 
 Positive PV   0.93    95% Confidence Interval (0.82 to 0.98) 
 Negative PV   1.0   95% Confidence Interval (0.97 to 1.0) 
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Among the three methods including clinical evaluation, 
radiological examination and induced sputum PCR , sputum PCR is 
having the highest sensitivity (100%), highest specificity (97%),highest 
positive predictive value (93%) and also highest negative predictive 
value(100%). 
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Chi square test showed the results of  PCR test were significant. 
PCR was positive in 2 patients who were missed in GMS staining. 
 
Those two showed good clinical response to TMP-SMX therapy. 
Among them, in one patient clinical diagnosis was made and in another 
one was missed in clinical and radiological evaluation.  
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OUTCOME:  
 
Of the total 151 HIV seropositive patients included in our study, 81 
were clinically diagnosed as suspected PCP.  
Of these 41 patients were confirmed microbiologically by sputum 
examination using Gomeri Methanamine Silver staining. 
 9 patients who were clinically negative for PCP (CD4 < 200) were 
positive microbiologically.  
These 90 patients were treated with TMP-SMX (20mg/kg/day of 
TMP in three divided doses). 
Patients who had severe PCP were treated with adjuvant 
corticosteroid along with non-invasive ventilation using a CPAP 
(Continuous Positive Airway Pressure) machine. 
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Outome 
 
recovered
died
 
 
Total number of PCP patients diagnosed clinically was 90.  
74 of 90(82.2%) patients recovered from the illness after treatment. 
16 0f 90(17.8%) patients died due to illness during the treatment. 
Average length of stay in hospital as inpatient – 21 days 
Average length of stay in IRCU (Intensive Respiratory Care Unit) 
– 7.5 days (n = 30) 
Among patients admitted in IRCU, 15 0f 90(16.7%) required Non 
Invasive ventilation (NIV)             
 
tc e
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DISCUSSION 
I.de Toro-Peinado et al have compared microscopic diagnosis and a 
real time PCR for the diagnosis of PCP with induced sputum and BAL. 
They analysed (39) patient with strong clinical suspicion of PCR. The 
concordance was 100% for BAL, but all the discrepant cases happened 
with induced sputum. 
  Juan Torres et al have done a blind comparison of PCR in HIV 
patients. In that study, PCR was done without the knowledge of the 
diagnosis.  
Depending upon the intensity of the banding pattern, PCR results 
were graded from ‘negative’ to 3+. Positive result at grade 1 or higher for 
all 18 individuals (100% sensitivity), at grade 2 or higher for all 18 
individuals (86.2% specificity).39 
Liebovitz et al., showed that staining methods and PCR having 
similar detection data in Broncho alveolar lavage specimen but in 
bronchial washing specimen, PCR was superior.40 
Lu et al., have compared 6 different PCR techniques, using BAL 
samples and showed nested PCR technique was the most sensitive assay 
for PCP diagnosis.41 
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A different single band ‘touch down’ PCR technique was 
demonstrated by Helweg lavsen et al., as having sensitivity and 
specificity for diagnosing PCP in AIDS patients. 
Rabodonirina et al., showed very good sensitivity (100%) but less 
specificity (77%) for rapid nested PCR technique in BAL samples of HIV 
patients. But in this study PCP diagnosis was done retrospectively.42 
But in our study we clinically and radiologically diagnosed PCP 
before doing PCR and staining. We used GMS staining as gold standard. 
Azouley E et al have done a prospective observational study in 
non-HIV patients with pulmonary infiltrates. They compared PCR with 
the giemsa staining and indirect immunofluorescence antibody.  
Results of their study showed the sensitivity of 87.2%, negative 
predictive value of 98.7%, positive predictive value of 51.5%. They 
concluded PCR performed similar to conventional methods for PCP 
diagnosis with high negative predictive value.43 
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Like all the above mentioned studies, our data are also showing 
high negative predictive value (100%) with negative predictive value 
(100%) with confidence interval between 0.97 and 1.0. 
Pierre Flori et al., have done a comparison study of RT-PCR, 
conventional PCR and different staining methods in BAL samples for 
PCP diagnosis sensitivity was 60% and specificity was 100% for staining, 
100% sensitivity and 87% specificity for conventional PCR and 100% 
sensitivity and 84.9% specificity for RT-PCR respectively.44 
Moreover, they concluded RT-PCR is an expeditious method, 
which took less than three hours with high sensitivity and having the 
utility of determining a cut-off for differentiating carrier state and disease. 
Our study showed higher sensitivity than most of the studies for 
GMS staining in induced sputum samples to diagnose PCP. 
A consensus statement by University of California expert panel 
showed the reduction in mortality, oxygenation and respiratory failure in 
moderate –to-severe PCP. 
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In a clinical study, Sabha Radhi et al. has shown  overall mortality 
of 11.6% for hospitalised PCP patients and 29% mortality especially for 
patients admitted in ICU. Several studies have demonstrated the same 
results. 
On comparing to this data, our study have  showed the slightly 
higher mortality (17.8%).The patients who presented with PCP and 
diagnosed as HIV seropositive are (48) more than known HIV 
seropositive patients came with PCP on comparing to those studies. 
Mallal SA et al demonstrated in pre HAART era, PCP found in 
newly diagnosed HIV patients had more severe form of PCP with low 
PaO2 and higher requirement of mechanical ventilation on comparing to 
PCP in known HIV patients.  
The reason postulated in Mallal et al. study may be the explanation 
for the high mortality in our study.37The known HIV seropositive patients 
with CD 4 lymphocyte count less than 200 cells/cubic mm were on 
cotrimoxazole prophylaxis along with HAART according to NACO 
guidelines.  
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LIMITATIONS 
The gold standard respiratory specimen for diagnosing PCP is 
Broncho Alveolar Lavage (BAL). But induced sputum was the 
respiratory specimen used in our study. 
Other staining methods, immunofluorescence methods were not 
compared in our study. 
The treatment outcome was measured only clinically. Sputum 
microscopy or PCR was not utilised for follow up after completion of 
treatment. Our study was done in a short period (five months). 
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CONCLUSION 
The sensitivity (78%), specificity (55%) and positive predictive 
value (40%), negative predictive value (87%) for clinical diagnosis of 
PCP in HIV seropositive patients are less on comparing with sputum 
GMS staining. 
The chest x ray diagnosis of PCP in HIV seropositive patients is 
also having low sensitivity (60%), specificity86%), PPV (62%) and NPV 
(86%) when comparing to GMS staining. 
For PCR in diagnosis of PCP in HIV seropositive patients, 
sensitivity (100%), specificity (97%), PPV (93), NPV (100%) are all 
showing highest values than radiological and clinical diagnosis. 
PCR or Gomori Methenamine silver staining should be used for 
diagnosing PCP whenever possible and to detect all cases of PCP in HIV 
patients without missing. 
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Among 90 patients who had treatment for PCP, mortality rate was 
17.8 % and 82.2 % of patients showed clinical improvement. 
These findings need further studies with large population to 
confirm. 
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 PROFORMA 
 
Name        :     
Age     :                     
Gender    :   
Occupation    : 
Address    : 
 
Phone No                                   : 
Height/Weight                           :  
Smoking      :  Yes / No  
Brand/quantity/Duration  : 
If stopped when?   : 
Alcohol use             :  Yes / No  
Brand/quantity/Duration  : 
If stopped when?   :   
Tobacco use                      : Chew/Snuff    
If yes no. of times/day           :  
 
COMORBID CONDITIONS 
Pregnancy   : Yes/No 
Peptic ulcer   : Yes/No 
Bronchial Asthma  : Yes/No 
Hypertension  : Yes/No 
Diabetes mellitus  : Yes/No 
 SYMPTOMS      
Cough: 
Fever: 
Sputum: 
Chest pain: 
Haemoptysis: 
Wheeze: 
Contact history of Tuberculosis: Yes/No 
Previous history of Tuberculosis treatment: 
If yes, Number of times of treatment: 
Duration of treatment: 
Regular /irregular: 
 
GENERAL EXAMINATION    :      
BMI 
Anaemia 
Lymphadenopathy 
Jaundice 
Spine 
Pedal oedema 
VITALS 
PR:                          BP: 
RR:              Temp: 
PULSE OXIMETRY: 
 
EXAMINATION OF RESPIRATORY SYSTEM 
 
Inspection     : 
Palpation     : 
Percussion     : 
Auscultation    : 
PER ABDOMEN    : 
 
CARDIOVASCULAR SYSTEM : 
CENTRAL NERVOUS SYSTEM : 
 
INVESTIGATIONS     
Haemoglobin    : 
WBC Count     : 
Chest X-Ray    : 
MANTOUX    : 
SPUTUM for AFB   : 
ELISA FOR HIV    : 
CD4 COUNT    : 
SPUTUM MICROSCOPY FOR PNEUMOCYSTIS JIROVECCI: 
(GMS STANINIG) 
PCR      : 
FINAL DIAGNOSIS   : 
CONSENT FORM 
 
 I Mr / Mrs / Miss / ____________________________ have understood 
the procedure read by the Doctors. I in my whole conscious awareness give 
consent for the procedure. I understand that the procedure is done in good faith 
for the best therapeutic results possible. I fully understand the consequences of 
the procedure. I can resign from the study at any point of time. 
         
 
Signature  
Name    :  
Date and Time  :  
 
Signature of Researcher   : 
 
 
 
 
 
 
 
 
 
 
 
யஒ~©தபவ 
ஆºெசய~பதைல~© 
எv.ஐ.வ. 
ேநாயாளக¶tகானநி­ேமாசிvெஜேராெவசிநிேமான
யாகzடறிதப¾ேசாதைனகம²ேநாயாளகள}உட
நிைலபறியஆº 
 
ஆராvசிநிைலய:   அரெநxசகேநா ம¯{¢வமைன ,  
 தாபரசானேடா¾ய, ெச}ைன.     
பuெப²பவ¾}ெபய  :  
பuெப²பவ¾}எz :  
பuெப²பவ (       ) இதைனtறிtகº :  
ேமேலறி~பட~பyள ஆவ}வவரuகஎனtவளtக~ப
yடத. எ}§ைடயச|ேதகuகைளtேகyகº, 
அதtகானத|தவளtகuகைள~ெபறºவா~பளtக~பyட¢. 
நா}இவாவத}னvைசயாக{தா}பuேககிேற}. 
எ|தகாரண{தினாேலாஎ|தகyட{தி´எ|தசyடvசிtக´tஉyப
டாமநா}இவாவஇ¯|¢வலகிt  ெகாளலாஎ}²அறி|
¢ெகாzேட}. 
இ|தஆºசப|தமாகேவா, 
இைதvசா|தேம´ஆºேமெகா¶ேபா¢ இ|தஆவபu
ெப²ம¯{¢வஎ}§ைடயம¯{¢வஅறிtைகையபா~பதஎ
zஅ§மதிேதைவயைலஎனஅறி|¢ெகாகிேற}. 
நா} ஆவ இ¯|¢வலகிtெகாzடா´இ¢ெபா¯|¢எனஅறிகி
ேற}. 
இ|தஆº¬லகிைடtதகவகைள­ப¾ேசாதைன«
ºகைள­ம²சிகிvைசெதாடபானதகவகைள­ம¯{¢வ
ேமtெகா¶ஆவபய}ப{திtெகாளºஅைத~பர¾tக
ºஎz«¸மன¢ட}சமதிtகிேற}. 
இ|தஆவபuெகாளஒ~©tெகாகிேற}. 
எனttெகாtக~பyடஅறிºைர~பநட|¢ெகாவ¢ட}இ|தஆ
ைவேமெகா¶ம¯{¢வஅணtஉ}னைம­ட}இ¯~ேப}எ}
²உ²திஅளtகி}ேற}.  
எ}உடநலபாதிtக~பyடாேலாஅல¢எதிபாராதவழtக{தி
மாறானேநாtறிெத}பyடாேலாஉடேனஅைதம¯{¢வஅணt{
ெத¾வ~ேப}எனஉ²திஅளtகிேற} .  
 
பuெப²பவ¾}ைகெயா~ப -------------------------------------    
இட ----------------------- ேததி ----------------- 
கyைடவரேரைக  
பuெப²பவ¾} ெபயம²வலாச ----------------------------------------------
------------------------------------ஆவாள¾}ைகெயா~ப ---------------------------------
---- இட ------------------------    ேததி --------------------ஆவாள¾}ெபய ----------
------------------------------------------------- 
 
 
 
ேநாயாளtகானதகவபவ 
 
மதி~ப¾யஐயா/ அைமய, 
 
உuகவ¯~ப{தி}ேப¾ “எv .ஐ .வ . 
ேநாயாளக¶tகானநி­ேமாசிvெஜேராெவசிநிேமான
யாகzடறிதப¾ேசாதைனகம²ேநாயாளகள}உட
நிைலபறியஆவ”பuேகபஅ}©ட}ேகytெகா
கிேறா. 
இ|தஆவஆரvசிேநாtக{¢tகாகதாuகப¾ேசாதைன
tஉyப{த~பவ க.த|தசிகிvைசதuக¶tெதாடu
க~ப. 
தuக¶tஇ|தஆவபuேககவ¯~பஇ¯|தாதாu
கஅ¯|¢ஒ~©தபவ{ைத~ப{¢~பா{¢tைக
ெயா~பஇபtேகytெகாகிேற}.. 
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